Tag Archives: eGFR

Chronic Kidney Disease (CKD) Diagnosis in Elderly Patients: Understanding eGFR Interpretation and Age-Specific Cutoffs

1. Introduction: The Growing Burden of CKD in an Aging Society

Chronic Kidney Disease eGFR interpretation in elderly patients, With the rapid aging of populations worldwide, the prevalence of chronic kidney disease (CKD) among elderly patients is also increasing. Traditionally, CKD has been diagnosed when the estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73m². However, distinguishing age-related decline in kidney function from pathological CKD remains a significant challenge.

Applying a strict eGFR <60 criterion to elderly individuals may lead to overdiagnosis, classifying age-related physiological decline as a disease. This article explores the importance of age-specific eGFR cutoffs, albuminuria, and comorbidities such as diabetes in diagnosing CKD in elderly patients.


2. eGFR Declines with Aging—Is It Always CKD?

(1) Understanding eGFR

  • The estimated glomerular filtration rate (eGFR) is a key marker of kidney function, typically calculated using serum creatinine or cystatin C.
  • While an eGFR below 60 mL/min/1.73m² is traditionally classified as CKD, aging must be considered when interpreting these values.

(2) The Problem with a Fixed eGFR <60 Criterion in Elderly Patients

  • Among patients in their 70s and 80s, it is common to observe eGFR values between 50–55 mL/min/1.73m², even in the absence of significant complications.
  • Using a fixed 60 mL/min/1.73m² threshold could lead to the misclassification of age-related decline as CKD, resulting in unnecessary tests and treatments.

3. Why Are Albuminuria and Comorbidities Important in CKD Diagnosis?

(1) The Role of Albuminuria (UACR)

  • Albuminuria (urinary albumin-to-creatinine ratio, UACR) is a sensitive marker of kidney damage.
  • If eGFR is low but albuminuria is absent, the decline may be due to natural aging rather than CKD. Conversely, patients with albuminuria, even with relatively preserved eGFR, have a higher risk of CKD progression.

(2) The Impact of Diabetes, Obesity, and Cardiovascular Risk

  • Comorbid conditions such as diabetes, obesity, and hypertension can accelerate kidney function decline beyond what is expected with normal aging.
  • Diabetes significantly increases the risk of albuminuria, making early detection and close monitoring essential for elderly diabetic patients.

(3) Greater eGFR Decline in Patients with Comorbidities

  • Patients with diabetes, obesity, and microalbuminuria exhibit a more rapid eGFR decline than their healthy counterparts.
  • Understanding eGFR trajectories over time is crucial to distinguishing between normal aging and pathological CKD.

4. Age-Specific eGFR Cutoffs: Benefits and Limitations

(1) Benefits

Prevention of Overdiagnosis: Helps differentiate normal age-related eGFR decline from true CKD, avoiding unnecessary treatments.
Personalized Risk Assessment: In an 80-year-old, an eGFR of 50 mL/min/1.73m² might be within an expected range, whereas the same value in a 40-year-old may indicate serious kidney disease.

(2) Limitations

Lack of Official Guidelines: Leading organizations such as KDIGO still use a fixed eGFR threshold of 60 mL/min/1.73m² for CKD diagnosis.
Risk of Missing Severe Cases: If age-specific cutoffs are too lenient, some patients who require dialysis or kidney transplantation may be overlooked.
Individual Variability: Muscle mass, nutrition, medications, and overall health impact eGFR, making a one-size-fits-all approach problematic.


5. Practical Applications: How Should We Interpret eGFR in Elderly Patients?

5.1 Use KDIGO Standards with Additional Markers

  • In clinical practice, eGFR <60 mL/min/1.73m² + albuminuria remains the primary CKD diagnostic criterion.
  • However, in elderly patients, using age-specific eGFR cutoffs can help reduce overdiagnosis.

5.2 Comprehensive Risk Assessment: Comorbidities, Albuminuria, and Decline Rate

  • Assessing diabetes, hypertension, cardiovascular disease, and albuminuria alongside eGFR provides a more accurate risk evaluation.
  • The rate of eGFR decline over time is more important than a single measurement—gradual declines suggest aging, while rapid declines suggest pathology.

5.3 Managing CKD in Elderly Patients: Conservative vs. Dialysis Approaches

  • Kidney transplantation is often not feasible in patients aged 65+, necessitating a careful approach to dialysis initiation.
  • Lifestyle modifications, medication adjustments, and patient-centered care should be prioritized to maximize remaining kidney function.
  • The decision between dialysis and conservative management should be made collaboratively between physicians and patients, considering quality of life and overall prognosis.

6. Conclusion: Moving Beyond a Fixed eGFR 60 Threshold

  • Age-related eGFR decline is not always indicative of CKD, and a rigid application of the 60 mL/min/1.73m² threshold may lead to overdiagnosis.
  • However, albuminuria, diabetes, cardiovascular conditions, and eGFR decline rates should be carefully evaluated before ruling out CKD.
  • Age-specific eGFR cutoffs provide useful reference points but should not replace comprehensive patient evaluation.

Ultimately, a patient-centered approach—rather than relying solely on a single eGFR value—is the key to optimizing kidney disease management in elderly populations.


References

  1. Herold JM, et al. “Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes.” Kidney International, 2024;106(4):699–711.
  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl, 2024;105(4S):S117–S314.

Disclaimer: This article summarizes research findings and clinical guidelines for general informational purposes only. For specific diagnosis and treatment, consult a medical professional.


Can Coffee and Tea Reduce Cancer Risk? coffee and cancer prevention

Semaglutide kidney protection– True or Illusion?

1. What is Semaglutide?

Semaglutide kidney protection, Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist originally developed for type 2 diabetes treatment. However, recent clinical trials indicate that it may also have cardiovascular and kidney-protective benefits, drawing significant attention in nephrology and endocrinology.

Common semaglutide-based medications include Ozempic and Wegovy, widely prescribed for both diabetes management and obesity treatment.


2. Semaglutide’s Kidney Protective Effects: Scientific Evidence

The FLOW (Evaluate Renal Function With Semaglutide Once Weekly) trial investigated semaglutide’s impact on chronic kidney disease progression in diabetic patients. The key findings were:

Reduced Risk of Kidney Failure

  • Semaglutide reduced the risk of kidney failure by 24%
  • Hazard ratio (HR): 0.76 (95% CI: 0.66–0.88, p = 0.0003)

Slower Decline in eGFR (Estimated Glomerular Filtration Rate)

  • Placebo group: -3.36 ml/min/1.73㎡ per year
  • Semaglutide group: -2.19 ml/min/1.73㎡ per year

Significant Weight Loss Observed

  • Average weight reduction of 4.1 kg (95% CI: 3.65–4.56 kg)

These results suggest that semaglutide may not only regulate blood sugar but also help slow kidney function decline.


3. Controversy: Is Kidney Protection an Illusion Caused by Weight Loss?

While these findings are promising, some researchers question whether semaglutide’s renal benefits are truly independent of its weight loss effects.

🔹 Weight Loss Can Artificially Improve eGFR Readings

  • Losing weight can temporarily increase eGFR measurements, making kidney function appear better than it actually is.
  • Thus, the reported improvements in eGFR might not reflect actual kidney protection but rather a calculation artifact.

🔹 The Study Did Not Fully Account for Weight Loss Effects

  • Since semaglutide induces weight loss, it is crucial to determine if kidney protection persists after adjusting for weight loss effects.
  • Further analysis is needed to separate true renal benefits from weight-related changes.

4. Future Research Directions and Key Questions

1️⃣ Does semaglutide’s kidney protection occur independently of weight loss?
➡️ Further studies should analyze kidney function changes after adjusting for weight loss effects.

2️⃣ How can we rule out weight-related measurement biases?
➡️ Researchers should compare kidney function data before and after removing body surface area indexing from eGFR calculations.

3️⃣ Do non-obese patients experience the same kidney benefits?
➡️ If semaglutide truly protects the kidneys, its benefits should also be observed in patients without obesity.


5. Could Semaglutide Become a Kidney Protection Therapy?

At present, semaglutide shows strong potential as a kidney-protective agent. However, further studies are essential to confirm whether its benefits are genuine or mainly driven by weight loss.

📌 What We Know So Far
✔️ Semaglutide may reduce the risk of kidney failure.
✔️ It slows eGFR decline in patients with CKD.
✔️ Weight loss might play a significant role in the observed benefits.

📌 Remaining Uncertainties
⚠️ eGFR improvements may be overestimated due to weight loss effects.
⚠️ More research is needed to confirm benefits in non-obese individuals.
⚠️ Long-term studies should evaluate true kidney protection beyond weight effects.


Conclusion: Semaglutide kidney protection?

Semaglutide presents exciting possibilities for kidney protection, but additional studies must clarify whether its effects are direct or weight loss-related. As research progresses, we will gain deeper insights into its true potential in CKD management.


The Risks and Management of Hypertension: If Family History